Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

By Lisa M. Coussens, B. Fingleton, L. Matrisian. Science, 2002

2,778 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/152f2645c55f15386b8c7a5932add39d0de5ffb2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion (2007, background): “Multiple sets of proteolytic enzymes, including matrix metalloproteinases (MMP) and serine and cysteine proteases, are upregulated and activated during cancer progressio”
Control of matrix metalloproteinase catalytic activity. (2007, background): “Significance Because they have the ability to act on extracellular matrix proteins, MMPs have been often implicated as contributing to tumor progression and metastasis, supposedly by breaking down tissue barriers that would otherwise restrain invasion (Coussens et al., 2002; Egeblad and Werb, 2002).”
From antimicrobial to anticancer peptides. A review (2013, background): “…important activity in what concerns remodeling of the extracellular matrix (ECM) in processes as tumor development, angiogenesis and metastatic progression (Coussens and Werb, 2002; Coussens et al., 2002; Egeblad and Werb, 2002; Visse and Nagase, 2003; Jang et al., 2011; Destouches et al., 2012).”
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. (2003, background): “Finally, matrix metalloproteinases have traditionally been thought to be important for late stages of tumorigenesis involving invasion and metastasis and, accordingly, MMP inhibitors have been used in a number of trials encompassing a variety of metastatic malignancies (Coussens et al., 2002).”
Extracellular matrix remodelling: the role of matrix metalloproteinases (2003, background): “However, studies with most of these compounds in advanced cancer were terminated in Phase III trials either because the patient survival was worse than that of the placebo group or because the compounds in combination with conventional therapy provided no advantage over conventional therapy alone [1”
Targeting proteases: successes, failures and future prospects (2006, methodology): “Third, the design of clinical trials was problematic and Phase I was often followed immediately by combined Phase II/III trials without sufficient time for good data analysis (reviewed in Ref”
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin signaling (2009, background): “, 2008), MMP inhibitors failed clinically (Coussens et al., 2002), indicating other ECM remodeling parameters regulate malignancy.”
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. (2009, background): “The reader is referred to a number of recent reviews for an extensive analysis of the design, development, and complexities that have slowed and limited the creation and mobilization of MMPIs into the clinic.(139,140) Several reasons might explain the unfavorable clinical outcomes in some of the MMP”
Molecular mechanisms of glioma invasiveness: the role of proteases (2003, background): “The outcome of the Phase I, II and III clinical trials of MPIs (as reviewed by Coussens et al”
Paradoxical roles of the immune system during cancer development (2006, background): “Clinical use of protease and COX2 inhibitors as anticancer therapeutics has been minimize”